散结镇痛胶囊联合米非司酮治疗50例子宫内膜异位症

目的：探讨散结镇痛胶囊联合米非司酮治疗子宫内膜异位症的临床疗效及安全性。方法：100例子宫内膜异位症患者随机分为观察组和对照组各50例。对照组予米非司酮口服,观察组在对照组基础上加用散结镇痛胶囊。观察两组患者治疗前后外周血中前列腺素（PGF2α）及CA125水平变化,比较两组疗效及药品不良反应。结果：治疗后,两组PGF2α、CA125水平及疼痛积分均较治疗前明显降低（P〈0.05或0.01）,且观察组各指标改善幅度明显大于对照组（P〈0.05）。观察组总有效率（94.00%）明显高于对照组（P〈0.05）,不良反应发生率（8.00%）明显低于对照组（P〈0.01）。结论：散结镇痛胶囊联合米非司酮治疗子宫内膜异位症疗效显著,安全性较高,值得临床推广应用。

Clinical Effect Observation of Sanjie Zhentong Capsule Combined with Mifepristone for 50 Cases Patients with Uterine Endometriosis

Objective：To observe the clinical efficacy arid g/ifety of sanjie Zhentong capsule combined with mife- pristone for patients with uterine endometriosis. Methods：One hundred patients with endometriosis were randomly divided into observation group and control group. The control group were given oral medication mifepristone. While , on the basis of the control group, the observation group were given Sanjie Zhentong capsule . The peripheral blood PGF2α and CA125 levels of the two groups were observed and recorded. The clinical efficacy and adverse drug reactions （ADRs） of the two groups were recorded . Results：Mter treatment , although the PGF2～ and CA125 of both groups were significantly lower （P 〈 0.05） , the prostaglandin（PGF2α） and CA125 of the observation group improved significantly greater than the control group （P 〈 0.05 ）. Two groups of patients pain scores were significantly lower （P 〈 0.01 ）, but after treatment pain score of the observation group improved significantly greater than the control group （ P 〈 0.05 ）. The total efficiency of the observation group （94.00%） was significantly higher than the control group（82.00% ）. There were statistically differences between ＇two groups（ P 〈0.05）. The ADRs incidence of the observation group（8. 00% ）was ob＇dously lower than the control group （P 〈 0.01 ）. Conclusion： Sanjie Zhentong capsule combined with mifepristone is worthy of clinical application be- cause it was proved to be clinical efficacy and safety.